alpha-Cyperone is a sesquiterpene ketone associated most strongly with Cyperus rotundus and cypriol-type aromatic materials. Compared with many minor oil constituents, it has a relatively active preclinical literature base: recent studies repeatedly describe anti-inflammatory, antioxidant, and neuroprotection-related findings in cell and rodent models, often centered on NF-kB suppression and Nrf2 or HO-1 activation. That evidence remains preclinical, with no basis for medical claims, but it is stronger than the evidence base for many archive sesquiterpenes.
Chemical identity and composition
PubChem lists alpha-cyperone as C15H22O. In the local archive, cypress-round-redistilled links alpha-cyperone to 7.9% based on a Cyperus rotundus composition source, which matches the broader literature pattern of alpha-cyperone as a characteristic Cyperus ketone.
Aroma and practical use
- Use the recorded woody, earthy, spicy, cypriol-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
microglial anti inflammatory activity
A 2018 study reported that alpha-cyperone markedly decreased TNF-alpha, IL-6, and IL-1beta production in LPS-stimulated BV-2 cells while inhibiting NF-kB activation and enhancing HO-1, Nrf2, and Akt expression.
Measured: TNF-alpha, IL-6, IL-1beta, NF-kB, HO-1, Nrf2, Akt
This experimental finding does not establish benefit, dose or safety in people using this blend.
brain inflammation related research
A Journal of Ethnopharmacology paper described alpha-cyperone from Cyperus rotundus as an effective candidate for reducing brain inflammation and linked the effect to destabilization of microtubule fibers.
Measured: inflammation reduction with proposed microtubule destabilization
This experimental finding does not establish benefit, dose or safety in people using this blend.
parkinson model neuroprotection
A 2023 study reported that alpha-cyperone alleviated dopaminergic neurodegeneration and reduced microglial inflammatory and oxidative-stress markers in an LPS-induced Parkinson-model rat system through Nrf2/HO-1 activation and NF-kB suppression.
Measured: motor dysfunction, dopaminergic neuron loss, inflammatory mediators, oxidative stress markers
This experimental finding does not establish benefit, dose or safety in people using this blend.
osteoarthritis related research
A 2021 osteoarthritis study reported that alpha-cyperone down-regulated NF-kB and MAPK signaling and prevented osteoarthritis progression in its experimental models.
Measured: cartilage degeneration and inflammatory pathway signaling
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo dedicated IFRA or RIFM constituent safety assessment specific to alpha-cyperone was located in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The reviewed alpha-cyperone literature is entirely preclinical and often uses purified research material at experimental doses, so wellness summaries should avoid extrapolating those findings to routine aroma use.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Public commercial listings sometimes mark alpha-cyperone as research-use material rather than a routine flavor or fragrance ingredient, which supports conservative handling language.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
akt nrf2 ho1 activation
A BV-2 microglial cell study reported that alpha-cyperone increased Akt, Nrf2, and HO-1 signaling while reducing inflammatory cytokine output after LPS challenge.
This experimental finding does not establish benefit, dose or safety in people using this blend.
nfkb and mapk suppression
Preclinical osteoarthritis and neuroinflammation studies report that alpha-cyperone lowers inflammatory mediator expression in parallel with reduced NF-kB and MAPK pathway activation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical studies specific to isolated alpha-cyperone were located in the reviewed public sources.
- The reviewed pharmacology literature is mechanistically richer than average for a sesquiterpene ketone, but it is still limited to cell and animal models.
- A July 2026 verification pass (RIFM Safety Assessment Program search, IFRA Cypriol Oil statement, and general web literature) did not locate a dedicated RIFM/IFRA fragrance ingredient safety assessment or authoritative dermal-limit figure for isolated alpha-cyperone; sensitization, phototoxicity, and penetration-enhancement data specific to this constituent also remain unlocated, so the existing 2% dermal_limit_pct stays unverified.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.